+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Manipulation of graft-versus-host disease for a graft-versus-leukemia effect after allogeneic bone marrow transplantation in AKR mice with spontaneous leukemia/lymphoma



Manipulation of graft-versus-host disease for a graft-versus-leukemia effect after allogeneic bone marrow transplantation in AKR mice with spontaneous leukemia/lymphoma



Transplantation 41(3): 301-310



Graft-versus-host (GVH) disease can result in a beneficial graft-versus leukemia (GVL) effect after bone marrow transplantation in patients with malignant disease. In this report, we used bacteria-free AKR (H-2k) mice bearing advanced spontaneous T cell leukemia/lymphoma as a moel to evaluate the GVH and GVL effects of bone marrow transplantation using fully incompatible SJL (H-2s) donors. A therapeutic GVL effect, accompanied by increased leukemia-free survival, was obtained only when 0.5 X 10(6) allogeneic lymphocytes (lymph node cells) were added to the marrow inoculum. Transplantation of allogeneic bone marrow without added lymph node cells (or use of syngeneic cells) resulted in a significant increase in leukemia relapse; increasing the dose of allogeneic lymph node cells to 2.0 X 10(6) resulted in significantly higher GVH-associated mortality. Survival and therapeutic benefits were obtained only when the intensity of the GVH reaction was carefully controlled by manipulation of alloreactive lymphocytes present in the marrow. These results suggest, indirectly, that T cell depletion may abolish any GVL effect of marrow transplantation, even if the donor is mismatched with the host at the major histocompatibility complex. The frequency in the spleen of cytotoxic T lymphocytes (CTL) reactive against host alloantigens was estimated using limiting-dilution microcytotoxicity assays at various times after transplantation of allogeneic bone marrow with and without added lymph node cells. The average frequency of CTL was highest in mice that were given marrow plus lymph node cells and tested within the first four weeks after transplantation. The level of CTL activity measured in vitro was dependent on the dose of lymphocytes injected and correlated with both the GVL and GVH effects in vivo. Down-regulation of CTL activity against host, but not third-party, alloantigens in vitro was observed under limiting dilution assay conditions, leading to the suggestion that host-specific regulatory cells may be present in these allogeneic bone marrow chimeras.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 040638975

Download citation: RISBibTeXText

PMID: 3513389

DOI: 10.1097/00007890-198603000-00005


Related references

Manipulation Of Graft-Versus-Host Disease For A Graft-Versus-Leukemia Effect After Allogeneic Bone Marrow Transplantation In Akr Mice With Spontaneous Leukemia/Lymphoma1. Transplantation 41(3): 301-310, 1986

Manipulation of graft vs. host disease for a graft vs. leukemia effect after allogeneic bone marrow transplantation in akr mice with spontaneous leukemia lymphoma. Transplantation 41(3): 301-310, 1986

The effect of HGF on graft-versus-host disease and graft-versus-leukemia after allogeneic bone marrow transplantation in acute lymphoblastic leukemia mice. Zhonghua Xue Ye Xue Za Zhi 26(7): 404-407, 2005

Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice. Zhonghua Xue Ye Xue Za Zhi 23(8): 411-414, 2002

Retrospective comparison of graft-versus-host disease and graft-versus-leukemia effect following allogeneic bone marrow and peripheral blood transplantation for acute myelogenous leukemia. Experimental Hematology (New York) 31(7 Suppl. 1): 87, 2003

The combination of fludarabine and cyclophosphamide in allogeneic bone marrow transplantation for murine leukemia is associated with less graft versus host disease but with effective graft versus leukemia. Blood 92(10 Suppl. 1 Part 1-2): 294B, 1998

Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2. Journal of Immunology 153(6): 2562-2567, 1994

Effect of bone marrow mesenchymal stem cells on acute graft versus host disease and graft versus leukemia after allogeneic bone marrow transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi 13(3): 404-407, 2005

Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 93(8): 2738-2747, 1999

Influence of ultraviolet-B irradiation on engraftment, graft-versus-host disease and graft-versus-leukemia effect in a rat model for allogeneic bone marrow transplantation. Bone: 801-807, Il 2, 1998

Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Bone Marrow Transplantation 17(3): 371-375, 1996

Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice. Zhonghua Xue Ye Xue Za Zhi 33(2): 88-93, 2012

Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Annals of Hematology 74(1): 1-6, 1997

Impact of HLA disparities on graft-versus-host disease and graft-versus-leukemia reaction in allogeneic bone marrow transplantation. Experimental Hematology 23(8): 862, 1995

T-cell depletion for allogeneic bone marrow transplantation: impact on graft-versus-host disease, engraftment, and graft-versus-leukemia. Journal of HematoTherapy 2(1): 27-42, 1993